KRYS stock forecast
Our latest prediction for Krystal Biotech, Inc.'s stock price was made on the Feb. 20, 2020 when the stock price was at 60.65$.
In the short term (2weeks), KRYS's stock price should underperform the market by -2.14%. During that period the price should oscillate between -9.39% and +8.44%.
In the medium term (3months), KRYS's stock price should underperform the market by -4.23%. During that period the price should oscillate between -33.92% and +26.18%.Get email alerts
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.17$ per share.
The book value per share is 4.12$
Three months stock forecastFeb. 20, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|